Trial Profile
A Phase IIa, Single-arm, Multicenter Study to Investigate the Clinical Activity and Safety of Avelumab in Combination With Cetuximab Plus Gemcitabine and Cisplatin in Participants With Advanced Squamous NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2022
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cetuximab (Primary) ; Cisplatin (Primary) ; Gemcitabine (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Merck KGaA
- 13 Sep 2022 Results (n=21) assessing the Clinical potential of circulating tumor DNA (based molecular response (MR) and baseline blood-based tumor mutational burden for monitoring response to first-line chemoimmunotherapy in advanced squamous non-small cell lung cancer presented at the 47th European Society for Medical Oncology Congress
- 07 Jun 2021 Status changed from active, no longer recruiting to completed.
- 15 Dec 2020 Planned End Date changed from 24 Feb 2021 to 28 May 2021.